A detailed history of Humankind Investments LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Humankind Investments LLC holds 1,939 shares of VRTX stock, worth $974,250. This represents 0.25% of its overall portfolio holdings.

Number of Shares
1,939
Previous 2,028 4.39%
Holding current value
$974,250
Previous $847,000 7.2%
% of portfolio
0.25%
Previous 0.23%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$392.81 - $485.53 $34,960 - $43,212
-89 Reduced 4.39%
1,939 $908,000
Q1 2024

May 08, 2024

SELL
$407.69 - $446.08 $96,214 - $105,274
-236 Reduced 10.42%
2,028 $847,000
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $15,092 - $18,069
-44 Reduced 1.91%
2,264 $921,000
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $13,189 - $14,135
-39 Reduced 1.66%
2,308 $802,000
Q2 2023

Aug 18, 2023

SELL
$314.42 - $351.91 $1.85 Million - $2.07 Million
-5,895 Reduced 71.52%
2,347 $825,000
Q2 2023

Aug 09, 2023

BUY
$314.42 - $351.91 $1.99 Million - $2.23 Million
6,327 Added 330.39%
8,242 $2.9 Million
Q1 2023

Apr 25, 2023

BUY
$283.23 - $323.1 $34,837 - $39,741
123 Added 6.86%
1,915 $603,000
Q4 2022

Jan 26, 2023

SELL
$285.76 - $321.48 $28,576 - $32,148
-100 Reduced 5.29%
1,792 $0
Q3 2022

Nov 09, 2022

BUY
$273.83 - $305.53 $15,334 - $17,109
56 Added 3.05%
1,892 $548,000
Q2 2022

Aug 05, 2022

BUY
$234.96 - $292.55 $8,223 - $10,239
35 Added 1.94%
1,836 $517,000
Q1 2022

May 09, 2022

SELL
$221.42 - $260.97 $83,918 - $98,907
-379 Reduced 17.39%
1,801 $470,000
Q4 2021

Mar 21, 2022

BUY
$177.01 - $223.45 $62,307 - $78,654
352 Added 19.26%
2,180 $479,000
Q3 2021

Mar 21, 2022

BUY
$181.39 - $202.99 $120,261 - $134,582
663 Added 56.91%
1,828 $332,000
Q2 2021

Mar 21, 2022

BUY
$187.49 - $221.1 $218,425 - $257,581
1,165 New
1,165 $235,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Humankind Investments LLC Portfolio

Follow Humankind Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Humankind Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Humankind Investments LLC with notifications on news.